PTC and CV Therapeutics Announce Collaboration and License Arrangement

News   Jun 13, 2006

 
PTC and CV Therapeutics Announce Collaboration and License Arrangement
 
 
 

RELATED ARTICLES

Bioethics Council Rules Heritable Genome Editing "Ethically Acceptable" In Certain Circumstances

News

A leading UK bioethics advisory body has weighed in on the debate around human genetic modification, concluding that heritable genome editing – modifying the DNA of an egg, sperm or embryo with changes that will be passed on to future generations – could be ‘morally permissible’ in humans, provided key ethical tests are met.

READ MORE

Genetic Factors Leading to Rare Bone Fusion Disorder Identified

News

Genome sequencing establishes multiple genes responsible for a rare condition that cause bone fusion

READ MORE

Key Ingredient in Diabetes Drug Modified to Improve Side Effects

News

Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy